Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate the Public on Risk Factors and Treatment Options for This Growing Disease
ZHEJIANG, China--(BUSINESS WIRE)--Gout is the most common form of inflammatory arthritis: More than 12 million Americans suffer from the disease, and this number continues to rise. But in addition to being prevalent, serious and extremely painful, gout is also widely misunderstood by the public.
May 22 marks Gout Awareness Day—a day set aside each year since 2006 to educate on the severity of gout and encourage proper diagnosis and treatment. The need to keep this disease top-of-mind remains strong, notes N. Lawrence Edwards, MD, MACP, MACR, chairman of the non-profit Gout Education Society, which founded Gout Awareness Day 19 years ago.
"Gout is a serious condition that can lead to permanent joint damage if left untreated. By raising awareness, we hope to encourage individuals to seek proper treatment and manage their condition effectively,' he explained. 'While this is a priority for the Gout Education Society each and every day, Gout Awareness Day enables us to join with like-minded individuals and organizations to advocate for better quality of life for patients and their families through education and awareness.'
Dr. William Shi, Founder, CEO and Chairman of Atom Therapeutics, which is developing new therapies to address gout, echoed Dr. Edwards' comments: 'Over the last 30 years, the percentage of people developing gout has been steadily rising, yet many don't understand their disease. Furthermore, only one in three report taking their daily medications as prescribed to lower uric acid levels. We support the Gout Education Society's efforts to improve the quality of care and minimize the burden of gout.'
Gout is caused by elevated uric acid levels. Over time, uric acid can accumulate and form crystals in the joints and other tissues—leading to painful flares. Untreated, gout can lead to permanent bone, joint and tissue damage, and other serious health issues, including kidney disease, heart disease and diabetes.
In conjunction with Gout Awareness Day, the Gout Education Society and Atom Therapeutics urge gout sufferers to learn more about the disease, seek immediate treatment and take ongoing steps to manage gout—with the most important step being to check uric acid levels every six months and aim for a healthy target of 6.0 mg/dL or below. While uric acid-lowering medications are typically needed to control gout and reduce future risks, those with gout should also make lifestyle changes—which includes following a healthy and balanced diet.
About Atom Therapeutics
Atom Therapeutics Ltd. is a fast-growing innovative drug company focused on the development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company's lead product, lingdolinurad (ABP-671), is in late-stage clinical development for treatment of chronic gout. Another small molecule ABP-745, for anti-inflammatory and autoimmune conditions, has completed Phase 1 clinical trials in the US and demonstrated good pharmacokinetics and safety, and has initiated Phase 2 clinical trial. For more information please visit: https://atomthera.us/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
"Maintaining Strong Bones Has Less To Do With Drinking Tons Of Milk": Experts Are Sharing What To Foods May Negatively Impact Your Bone Density
My grandmother has osteoporosis, along with 10 million other Americans diagnosed with the disease and 43 million others with low bone mass. Not wanting to follow in her hobbled footsteps, the rest of the women in the family are taking precautions, including consuming the recommended amount of calcium (more isn't necessarily better), adding weight-bearing exercises to our exercise regimens and attending regular doctor checkups. But according to orthopedic specialists, protecting and maintaining strong bones has less to do with drinking tons of milk (those Got Milk campaigns certainly had their intended effect) and more to do with avoiding foods and beverages that can impact our bone density. Folks concerned about osteoporosis often add calcium and vitamin D to their diets, but these supplements could hurt your bone health rather than help if not taken as needed. Dr. Liz Matzkin, associate professor at Brigham and Women's Hospital in the Department of Orthopedic Surgery in Boston, explained: 'Although calcium and Vitamin D is important to maintain bone health, exceeding the recommended doses per day can backfire and be harmful rather than beneficial. Calcium and vitamin D requirements are age dependent, so make sure you are aware of the optimal dose for you.' She advised that, for ages 50 and over, the recommendations are 1,000 milligrams per day of calcium and 800 to 1000 international units per day of vitamin D. Below, orthopedic surgeons and specialists share the foods they avoid to help lessen their risk of osteoporosis. Alcohol Related: This Picky Eater Showdown Will Be Tough For People Without Refined Palates We don't blame you if you're totally confused about whether alcohol is a healthy or unhealthy addition to your diet. Whether you've heard it's beneficial for heart health or are concerned about its effect on the liver, Matzkin cautions that sipping a few glasses of pinot or chugging lagers can negatively affect bone health. 'An increased consumption of alcohol can alter the body's ability to absorb important nutrients that are actually beneficial to bone health, such as calcium, vitamin D and magnesium,' she explained. While calcium and vitamin D often get the spotlight in this area, our sex hormones, like testosterone in men and estrogen in women, are also critical for ensuring strong bones. Angelina Waller, a physician assistant at Advanced Orthopedics in Denver, explained that alcohol 'slows the bone remodeling cycle and disrupts hormone levels.' If you do like to imbibe, Matzkin recommends no more than one alcoholic beverage per day (which is the maximum amount women should be drinking anyway, according to the Centers for Disease Control and Prevention). Older folks and those who are at risk of bone breakage should be especially cautious. 'Lastly, if you consume too much alcohol, there is a higher risk of falling and injuring or fracturing a bone,' Matzkin said. A 2018 study found a link between alcohol consumption and hip fractures. Caffeine Related: If Your Fruit And Vegetable Knowledge Is Actually Good, Prove It By Getting 22/27 Of These Questions Right While America runs on coffee, it doesn't fuel our bones. And not just coffee. Add energy drinks, soda, tea and supplements or any product with caffeine to the hit list. Just like alcohol, the idea isn't abstention but moderation. 'Caffeine has been shown to increase calcium loss and decrease calcium absorption, both of which negatively influence bone health,' Matzkin said. 'Consider decaffeinated coffee or tea options if you just need something to warm you up or, even better, a tall glass of water.' The Food and Drug Administration recommends no more than 400 milligrams of caffeine a day (about 4-5 cups of coffee), which is a good guideline to use for bone health too. The bone builder vitamin D is also affected by caffeine, which can interfere with absorption. 'Caffeine causes decreased calcium absorption and increased calcium loss in the urine,' Waller said. Soda, particularly cola, is also a culprit of bad bone health. A 2006 comparative study found that drinking cola (including diet versions!) was associated with significantly lower bone mineral density in women. The level of consumption is related to the problem: The more cola the women drank, the more significant its impact. 'Soda contains sugars and can also contain phosphoric acid and caffeine,' Matzkin said. 'All of which fail to have any health benefits and, if consumed in large quantities, will result in negative health consequences.' Wheat Bran It may come as a surprise that heart-healthy wheat bran can have a negative effect on bone health. 'Wheat bran has high levels of phytates, which can prevent calcium absorption,' Matzkin explained. Many people eat wheat bran because it's high in dietary fiber, which is essential for keeping you regular, decreasing heart disease and even preventing colon cancer, all important considerations for many Americans. Thankfully, if you're a consumer of oat bran (which is different from wheat bran), it doesn't have the same deleterious effects on bones as wheat bran, according to Matzkin, as it doesn't contain high levels of phytates. Phytates are a type of anti-nutrient naturally found in plants. Many of your favorite veggies and legumes (from kale and cabbage to beans and peanuts) contain compounds that reduce the absorption of other nutrients. Pseudoscience makes a big deal out of avoiding these compounds, but for the most part, there's no reason to avoid these otherwise-healthy foods. Beans, spinach and beets also contain anti-nutrients that can decrease calcium absorption, but soaking (in the case of dried beans) or cooking (for raw spinach and beets) lessens their impact, according to Waller. 'Beans and wheat bran contain phytates, and spinach and beets contain oxalates that decrease calcium absorption as they bind to the calcium,' she said. If you want to reduce the phytates in wheat bran, you can try soaking, sprouting or fermenting it. Since it has tons of other benefits, there's no need to completely remove it from your diet, just moderate your intake. 'As with almost all foods, moderation is key,' Matzkin said. 'No need to completely eliminate wheat bran from the diet, but understanding that it can affect [calcium] absorption should prompt supplementation with other [calcium]-rich foods.' Salt Whether your tastes run salty or sweet or salty-sweet, the white stuff is typically associated with high blood pressure rather than bone loss. But it really should be a consideration for bone health, especially for older and at-risk groups. 'Be aware of salt that can be hidden in meats, snacks and processed foods such as cold cuts,' Matzkin said. 'Consuming excessive amounts of salt (more than 2,300 milligrams per day) can lead to calcium loss from your bones.' According to a 2018 study by the Journal of the American College of Nutrition, increased sodium consumption significantly increased the risk of osteoporosis. To put that in perspective, 2,300 milligrams per day is equal to 1 teaspoon of table salt, according to the FDA. On average, Americans are eating 1.5 times that amount. This post originally appeared on HuffPost. Also in Food: I'm Not Calling You Uncultured, But If You Can't Pass This International Food Also in Food: People Are Sharing The "Unneccessary" Cooking Rules They Stopped Following Ages Ago Also in Food: If You Can't Name At Least 10 Of These Fruits, You've Got The Taste Buds Of A Toddler
Yahoo
3 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
